J&J, Legend report Carvykti cut death risk by 45% in multiple myeloma study

Johnson & & Johnson ( NYSE: JNJ) and Legend Biotech ( NASDAQ: LEGN) stated a long-lasting research study revealed their cell treatment Carvykti minimized the threat of death by 45% in specific numerous myeloma clients.

Three-year follow-up information from a Stage 3 research study revealed clients with